Canada Post Corp Registered Pension Plan Buys 16,254 Shares of Boston Scientific Corporation $BSX

Posted by Brian Himes on Aug 13th, 2026

Boston Scientific logo Canada Post Corp Registered Pension Plan increased its stake in Boston Scientific Corporation (NYSE:BSX – Free Report) by 19.0% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 101,583 shares of the medical equipment provider’s stock after buying an additional 16,254 shares during the quarter. Canada Post Corp Registered Pension Plan’s holdings in Boston Scientific were worth $4,336,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. Renaissance Group LLC bought a new stake in shares of Boston Scientific during the fourth quarter worth about $28,064,000. PensionDanmark Pensionsforsikringsaktieselskab increased its stake in shares of Boston Scientific by 9.9% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after buying an additional 28,961 shares during the period. Meiji Yasuda America Inc bought a new position in Boston Scientific in the 4th quarter valued at approximately $4,708,000. Harvest Portfolios Group Inc. boosted its position in Boston Scientific by 6.1% during the 4th quarter. Harvest Portfolios Group Inc. now owns 597,341 shares of the medical equipment provider’s stock worth $56,956,000 after buying an additional 34,598 shares during the period. Finally, LBP AM SA boosted its position in Boston Scientific by 8.4% during the 4th quarter. LBP AM SA now owns 434,393 shares of the medical equipment provider’s stock worth $41,419,000 after buying an additional 33,534 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX opened at $51.40 on Thursday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The firm’s fifty day simple moving average is $45.94 and its two-hundred day simple moving average is $59.69. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The stock has a market capitalization of $74.49 billion, a P/E ratio of 20.81, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period last year, the company posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has approved a share repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Jefferies Financial Group decreased their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, June 24th. Bank of America cut their price target on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Wells Fargo & Company decreased their price objective on Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a report on Thursday, July 30th. Canaccord Genuity Group lowered their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, Truist Financial cut their target price on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Read Our Latest Stock Report on Boston Scientific

Insiders Place Their Bets

In other Boston Scientific news, Director Cheryl Pegus bought 1,770 shares of the stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Edward J. Ludwig purchased 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 204,322 shares of company stock valued at $9,939,221. Company insiders own 0.34% of the company’s stock.

About Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.